Objective To etiologically diagnose and analyze two suspected patients of brucellosis and provide a etiologic basis for confirmation of the patients and control of brucellosis in Guizhou Province.Methods Antibody leve...Objective To etiologically diagnose and analyze two suspected patients of brucellosis and provide a etiologic basis for confirmation of the patients and control of brucellosis in Guizhou Province.Methods Antibody levels of Brucella in the suspected patients were determined by agar plate agglutination test and tube agglutination test.展开更多
Tumor heterogeneity has increasingly underscored the urgent need for personalized medicine,prompting the Food and Drug Administration(FDA)to approve in vitro companion diagnostics(CDx)for patient stratification.This e...Tumor heterogeneity has increasingly underscored the urgent need for personalized medicine,prompting the Food and Drug Administration(FDA)to approve in vitro companion diagnostics(CDx)for patient stratification.This evolving landscape has gradually transitioned towards imagingbased CDx,which is now further integrated with therapeutic modalities,culminating in the emergence of companion theranostics(CTx).In this review,we systematically elucidate the development of CTx and provide the first formal definition of this concept,thereby establishing a clear framework that distinguishes it from existing diagnostic approaches.We particularly emphasize the design principles underlying CTx by introducing activation strategies that leverage tumor active markers and treatmentactivation mechanisms to enhance therapeutic precision.Finally,we address key challenges that remain,including the markers discovery,fine-tuning probes design,and regulatory approvals for clinical applications.We hope the insights shared in this review will contribute to the design of CTx for oncology,advancing personalized medicine.展开更多
文摘Objective To etiologically diagnose and analyze two suspected patients of brucellosis and provide a etiologic basis for confirmation of the patients and control of brucellosis in Guizhou Province.Methods Antibody levels of Brucella in the suspected patients were determined by agar plate agglutination test and tube agglutination test.
基金supported by the National Natural Science Foundation of China(No.82372116)China Postdoctoral Science Foundation(No.2023M742404)+2 种基金Postdoctoral Fellowship Program of CPS Funder(No.GZB20230449)Shenzhen Science and Technology Program(Nos.JCYJ20220818095806014 and KQTD20190929172538530)Research Team Cultivation Program of Shenzhen University(No.2023QNT019).
文摘Tumor heterogeneity has increasingly underscored the urgent need for personalized medicine,prompting the Food and Drug Administration(FDA)to approve in vitro companion diagnostics(CDx)for patient stratification.This evolving landscape has gradually transitioned towards imagingbased CDx,which is now further integrated with therapeutic modalities,culminating in the emergence of companion theranostics(CTx).In this review,we systematically elucidate the development of CTx and provide the first formal definition of this concept,thereby establishing a clear framework that distinguishes it from existing diagnostic approaches.We particularly emphasize the design principles underlying CTx by introducing activation strategies that leverage tumor active markers and treatmentactivation mechanisms to enhance therapeutic precision.Finally,we address key challenges that remain,including the markers discovery,fine-tuning probes design,and regulatory approvals for clinical applications.We hope the insights shared in this review will contribute to the design of CTx for oncology,advancing personalized medicine.
